Premature ovarian insufficiency (POI) and early menopause (EM) dramatically compress the window of estrogen exposure, driving accelerated cardiovascular disease, osteoporosis, cognitive decline, psychological morbidity, and shortened lifespan compared to women reaching natural menopause. A joint position paper from FIGO and the International Menopause Society argues that current hormone therapy protocols — largely borrowed from research on older postmenopausal women — are inadequate, fragmented, and frequently delayed, and proposes reclassifying POI/EM as chronic endocrine conditions and sentinel markers of accelerated biological aging.
This position paper carries significant clinical weight because it formalizes what observational data have suggested for over a decade: estrogen deprivation at 20–40 years of age is physiologically distinct from menopause at 51, and treating them identically misses the opportunity for meaningful disease prevention. The Women's Health Initiative's risk findings, which shaped a generation of prescribing caution, were derived from women averaging 63 years old — a population profile wholly irrelevant to POI. The call for "timely initiation, adequate dosing, and long-term continuation" directly challenges the minimization culture that has left many young women undertreated. While position papers are advocacy documents rather than primary evidence, their endorsement by two major global bodies signals a potential paradigm shift in clinical guidelines. Practically, women diagnosed with POI should be assessed for HT eligibility promptly and managed within multidisciplinary frameworks. The equity dimension — ensuring global access to care — adds meaningful public health urgency.
